Diagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 Variants
Open Access
- 25 December 2025
- journal article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (3) , 734-742
Abstract
Objective: Deficiency of adenosine deaminase 2 (DADA2) is a monogenic autoinflammatory disease manifested as polyarteritis nodosa, stroke, and bone marrow failure. Leveraging an international cohort of 200 DADA2 cases, we aimed to characterize the diagnostic utility of a plasma ADA2 enzyme activity assay and understand the implications of residual ADA2 activity. Methods: Data were collected from individuals who underwent ADA2 testing from 2018 to 2025. Plasma ADA2 activity was determined using an established spectrophotometric assay. ADA2 variants were analyzed in transfected cells by enzyme assay and western blotting. Results: We determined that plasma ADA2 activity is 99.0% and 96.0% sensitive and 99.7% and 98.8% specific in distinguishing genetically confirmed DADA2 cases from controls and carriers, respectively. Eighteen individuals with DADA2 (9%) possessed detectable ADA2 activity, including several cases with levels seen in carriers. Residual ADA2 activity was associated with the vasculitis/inflammatory phenotype but not with disease severity. Genotype analysis revealed that 14 of 18 cases with residual plasma activity possessed at least one hypomorphic missense variant with greater than 20% residual ADA2 function when overexpressed in 293T cells, often occurring in trans with a more deleterious variant. In vitro analysis revealed that missense ADA2 variants exert variable dominant‐negative effects by forming large intracellular protein aggregates via disulfide bond formation at a cysteine residue (Cys408). Conclusion: We confirmed the utility of plasma ADA2 activity as a diagnostic assay and showed that the inflammatory phenotype of DADA2 occurred in cases with residual activity. In vitro findings illustrate potential interactions of ADA2 variants to synergistically disrupt protein function.Keywords
Funding Information
- Rheumatology Research Foundation (Innovative Research Award)
- Rheumatology Research Foundation (R‐Bridge Award)
This publication has 27 references indexed in Scilit:
- Adenosine deaminase 2 regulates the activation of the toll-like receptor 9 in response to nucleic acidsFrontiers of Medicine, 2024
- Clinical Symptoms, Laboratory Parameters and Long-Term Follow-up in a National DADA2 CohortJournal of Clinical Immunology, 2023
- Evaluation and Management of Deficiency of Adenosine Deaminase 2JAMA Network Open, 2023
- Mechanisms of vascular inflammation in deficiency of adenosine deaminase 2 (DADA2)Seminars in Immunopathology, 2022
- Enzyme activity in dried blood spot as a diagnostic tool for adenosine deaminase 2 deficiencyAnalytical Biochemistry, 2021
- Deficiency of Adenosine Deaminase 2 in Adults and Children: Experience From IndiaArthritis & Rheumatology, 2020
- Sequence‐Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in ADA2Arthritis & Rheumatology, 2020
- Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and TreatmentJournal of Clinical Immunology, 2018
- Deficiency of Adenosine Deaminase Type 2: A Description of Phenotype and Genotype in Fifteen CasesArthritis & Rheumatology, 2016
- Automated enzymatic measurement of adenosine deaminase isoenzyme activities in serumAnalytical Biochemistry, 1990